[EN] METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS<br/>[FR] PROCÉDÉS D'UTILISATION D'ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE DANS LA TRIAZOLO-PYRAZINYLE POUR DES TROUBLES FIBROTIQUES
申请人:MERCK SHARP & DOHME
公开号:WO2017200857A1
公开(公告)日:2017-11-23
Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R1, R2, R3, R4, and R5 are as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.
[EN] IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] DÉRIVÉS D'IMIDAZO-PYRAZINE UTILES EN TANT QU'ACTIVATEURS DE GUANYLATE CYCLASES SOLUBLES
申请人:MERCK SHARP & DOHME
公开号:WO2015187470A1
公开(公告)日:2015-12-10
A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof.
Compounds, pharmaceutical compositions and uses thereof
申请人:HIMMELSBACH Frank
公开号:US20120322784A1
公开(公告)日:2012-12-20
The present invention relates to compounds of formula I,
wherein the groups R
1
, L
P
, L
Q
, X
1
, X
2
, X
3
, Ar and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.